Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy

Zhao, Pengcheng; Xie, Long-Yan; Yu, Li; Wang, Ping

doi:10.1016/j.gendis.2022.12.008

Cited by 4 publications

(3 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Signal regulatory protein alpha (SIRPα), expressed on macrophages, triggers a “don’t eat me” signal by interacting with the cluster of differentiation 47 (CD47) and further enables immune evasion for lymphoma cells [ 261 ]. Antibodies, fusion proteins, small molecule inhibitors, and peptides targeting the CD47-SIRPα axis, together with PD-1(IBI322, HX009), might be promising immunotherapeutic strategies in future lymphoma therapy [ 262 ]. A better comprehension of the clinical relevance of metabolic process and microenvironment would help us overcome the barriers to lymphoma treatment and achieve better efficacy and prognosis.…”

Section: Discussionmentioning

confidence: 99%

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma

Pang

Xu-Monette

et al. 2023

IJMS

View full text Add to dashboard Cite

Lymphoma is a heterogeneous group of diseases that often require their metabolism program to fulfill the demand of cell proliferation. Features of metabolism in lymphoma cells include high glucose uptake, deregulated expression of enzymes related to glycolysis, dual capacity for glycolytic and oxidative metabolism, elevated glutamine metabolism, and fatty acid synthesis. These aberrant metabolic changes lead to tumorigenesis, disease progression, and resistance to lymphoma chemotherapy. This metabolic reprogramming, including glucose, nucleic acid, fatty acid, and amino acid metabolism, is a dynamic process caused not only by genetic and epigenetic changes, but also by changes in the microenvironment affected by viral infections. Notably, some critical metabolic enzymes and metabolites may play vital roles in lymphomagenesis and progression. Recent studies have uncovered that metabolic pathways might have clinical impacts on the diagnosis, characterization, and treatment of lymphoma subtypes. However, determining the clinical relevance of biomarkers and therapeutic targets related to lymphoma metabolism is still challenging. In this review, we systematically summarize current studies on metabolism reprogramming in lymphoma, and we mainly focus on disorders of glucose, amino acids, and lipid metabolisms, as well as dysregulation of molecules in metabolic pathways, oncometabolites, and potential metabolic biomarkers. We then discuss strategies directly or indirectly for those potential therapeutic targets. Finally, we prospect the future directions of lymphoma treatment on metabolic reprogramming.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma

Pang

Xu-Monette

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Normal cells including red blood cells and hematopoietic stem cells express CD47 to protect themselves from phagocytosis [56]. Engagement of CD47 and SIRPα results in anti-phagocytotic activity, known as the "Don't eat me" mechanism [57]. High CD47 expression in malignancies correlates with poor prognosis [53].…”

Section: Anti-cd47 Mabmentioning

confidence: 99%

“…High CD47 expression in malignancies correlates with poor prognosis [ 53 ]. Disruption of CD47-SIRPα binding is one of the immunotherapeutic approaches to trigger phagocytosis and inhibit tumor growth [ 58 , 59 ].…”

Section: Mabsmentioning

confidence: 99%

Promising immunotherapeutic approaches for primary effusion lymphoma

Panaampon,

Okada

2024

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Primary effusion lymphoma (PEL) is a large B-cell neoplasm usually presenting as a serious effusion in body cavities without detectable tumor masses. It is an AIDS-related non-Hodgkin’s lymphoma (HL) with human herpes virus 8 (HHV8)/Kaposi sarcoma-associated herpes virus (KSHV) infection. A combination antiretroviral therapy (cART) prolongs the lifespan of AIDS and AIDS-related malignant lymphoma patients, but PEL continues to have a dismal prognosis. PEL showed disappointing outcomes with standard chemotherapy such as CHOP or CHOP-like regimens. A PEL status highlights the urgent need for new therapeutic approaches and treatment strategies and improve clinical outcomes. This review discusses the current knowledge and some recent clinical trials for PEL in the platform of immunotherapy as well as promising future immunotherapeutic approaches for PEL.

show abstract